Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$23.4M | -$16.2M | -$17.7M | -$19.8M | -$21.6M | -$23.8M | -$36.9M | -$40.9M | -$42.4M | -$36.6M |
| Net income | -$18.8M | -$12.8M | -$16.7M | -$19.5M | -$22.2M | -$23.2M | -$36.9M | -$69.0M | -$18.9M | -$174M |
| EPS (diluted) | -$24.67 | -$2.18 | -$3.59 | -$2.55 | -$1.35 | -$0.96 | -$1.08 | -$1.91 | -$0.89 | -$4.80 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.6M | -$9.19M | -$10.6M | -$15.6M | -$18.3M | -$23.6M | -$32.5M | -$47.4M | -$37.6M | -$25.8M |
| Capital expenditures | $279K | $58.0K | $875K | $224K | $824K | $1.30M | $2.21M | $8.14M | $1.88M | $542K |
| Free cash flow | -$10.9M | -$9.25M | -$11.5M | -$15.8M | -$19.1M | -$24.9M | -$34.7M | -$55.6M | -$39.4M | -$26.3M |
| Dividends paid | $80.0K | — | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.71M | $5.13M | $9.66M | $6.03M | $9.65M | $10.3M | $14.9M | $13.5M | $9.29M | $8.69M |
| Total assets | $18.2M | $11.1M | $14.5M | $25.5M | $39.5M | $69.8M | $95.8M | $98.4M | $86.4M | $76.9M |
| Total liabilities | $8.43M | $3.41M | $6.85M | $10.9M | $20.7M | $44.4M | $59.8M | $130M | $134M | $295M |
| Shareholders' equity | $9.72M | $24.3M | $7.69M | $14.6M | $18.9M | $25.4M | $36.1M | -$32.1M | -$48.0M | -$219M |
| Retained earnings | -$381M | -$394M | -$138M | -$158M | -$180M | -$203M | -$240M | -$309M | -$328M | -$502M |
| Shares (wtd avg diluted) | 984K | 6.57M | 4.65M | 8.01M | 16.4M | 24.1M | 34.3M | 36.1M | 59.1M | 36.2M |
Every figure is extracted from Armata Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.